VOCSN is a highly customizable respiratory system and is the first of its kind to eliminate the need for multiple medical devices
SANTA CLARA, Calif. — September 19, 2017 — Based on its recent analysis of the respiratory care market, Frost & Sullivan recognizes Ventec Life Systems with the 2017 North American Frost & Sullivan Award for New Product Innovation. Ventec Life Systems received Food and Drug Administration (FDA) clearance for its portable unified respiratory system, VOCSN, in April 2017. The innovative product combines a critical care ventilator, 6 L/min equivalent oxygen concentrator, Touch Button Cough™ assist, hospital grade suction, and high performance nebulizer in a single device, enabling improved quality of care and substantial cost savings for patients, payers, and caregivers. The unified device not only lowers the cost of acquisition, storage, maintenance, and training, but also consumes less power than systems that require multiple devices.
VOCSN is fully customizable, patients can get all five therapies or just the mix of therapies needed. Each therapy in VOCSN had to be redesigned to be smaller, more energy efficient, and integrated into one system to make care management easier for caregivers and more comfortable for patients. VOCSN can include any mix of five therapies common for ventilator patients:
- Critical care ventilator: Offers advanced invasive, noninvasive, and mouthpiece ventilation with responsive leak and circuit compensation for patients 5 kg and above.
- Internal oxygen concentrator: Together with the Oxygen Direct™ system, delivers the equivalent of 6 L/min of oxygen or 40% FiO2. They system is up to two times more energy efficient than other portable oxygen concentrators.
- Touch Button Cough™ assist: The Ventec One-Circuit™ allows patients to use the same circuit for ventilation and cough, making Touch Button Cough™ therapy possible in seconds, rather than minutes.
- Hospital-grade suction system: Facilitates airway clearance with consistent high flow vacuum pressure similar to hospital suction systems. VOCSN includes an advanced sound muffler that makes the suction system more than three times quieter than traditional suction machines.
- High-performance nebulizer: Ensures accurate ventilation through automatic airflow compensation with the ventilator and features an automatic time duration turn off to stop the nebulizer once the therapy is complete.
“VOCSN’s battery life of up to nine hours and weight of 18 lbs makes it both lightweight and portable, facilitating its use in multiple care settings such as hospitals, sub-acute care facilities, long-term care facilities, transport, and patients’ homes,” said Frost & Sullivan Senior Research Analyst Tanvir Jaikishen. “It also demonstrates high customizability in treating a range of conditions such as chronic respiratory diseases, autoimmune diseases, and various forms of muscular dystrophy and spinal cord injuries. VOCSN demonstrates a long overdue move to develop integrated medical devices that are easier to use in the hospital and home matching similar advacements more common with consumer electronics rather than complicated and sometimes confusing medical devices.”
VOCSN includes an internal thereapy tracker that records the use of all five therapies so caregivers can better manage patient compliance to the doctor’s orders. In the future, this information could be easily shared across Bluetooth and Wi-Fi for facility management or remote patient care. This functionality could be activated once the regulatory environment for remote connectivity of life support devices is defined and security standards are established.
Significantly, patients are not required to purchase all five functionalities of VOCSN and only need to invest in the features they require. Ventec is currently working with stakeholders in the payer and provider space to design pricing structures that ensure affordability and a simplified purchasing process, without compromising quality.
“Ventec Life Systems is currently working with patients in the United States and plans to continue their growth in Europe and Asia in a phased manner between 2017 and 2018,” noted Jaikishen. “The rapidly aging populations in European nations and the rise in incidence of respiratory and lifestyle diseases in other developing countries have positioned VOCSN nicely to emerge a key player in the global market.”
Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it gives customers, which, in turn, raises customer acquisition and overall market penetration potential.
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Ventec Life Systems
Ventec Life Systems is redefining respiratory care to improve patient outcomes and reduce caregiver challenges in the hospital and home. Ventec’s leading product, VOCSN, seamlessly integrates five separate devices including a ventilator, oxygen concentrator, cough assist, suction, and nebulizer into one unified respiratory system. The team’s history of patient-centric design includes more than 10 care changing respiratory devices and more than 40 patents. Learn more at VentecLife.com and connect with Ventec on Facebook, LinkedIn, and YouTube.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.
Contact:
Claudia Toscano
P: 210.477.8417
E: [email protected]
